Cancer

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastatic suppressors BigH3 and TIPE2, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 15/January/2018, 4.30 am
Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastatic suppressors BigH3 and TIPE2, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 15/January/2018, 4.30 am 960 720 Dr Boomi's Genom-2-Discovery Center

From significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastatic suppressors GRHL3 and long ncRNA GAS5, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 13/January/2017, 11.20 pm
Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastatic suppressors GRHL3 and long ncRNA GAS5, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 13/January/2017, 11.20 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing Shikonin, Idasanutlin, Rhamnetin, & Cisplatin [SIRC] inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 12/January/2017, 11.45 pm
Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing Shikonin, Idasanutlin, Rhamnetin, & Cisplatin [SIRC] inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 12/January/2017, 11.45 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, Harvard University, Oxford St., Cambridge,…

read more

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastatic suppressors RECK and CADM1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 12/January/2017, 11.11 pm
Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastatic suppressors RECK and CADM1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 12/January/2017, 11.11 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of DNA-repair protein hMSH and the apoptosis-inducing protein FasL, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 11/January/2017, 11.04 pm
Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of DNA-repair protein hMSH and the apoptosis-inducing protein FasL, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 11/January/2017, 11.04 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastasis suppressors BTG2 and INK4a/p16, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 10/January/2017, 12.13 am
Molecular therapy for Metastatic cancers: Torasemide, an anti-hypertensive drug, increases the expression of tumor/metastasis suppressors BTG2 and INK4a/p16, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 10/January/2017, 12.13 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more
Start Typing